RE:RE:All this talk about S&PFirst of all queertard, 2021 was 4.5 months ago - not 4.5 years, not sure what your point is. Wasn't the original Tilray thing-y announced in 2021? You're such a clown.
As for the 'Tilray partnership', if you're referring to Tilray assuming $200 million of debt, that's hardly a 'partnership'. It simply transferred debt from High Trail to Tilray and while it delayed the inevitable for Hexo - they had to give up 35% ownership, valuing the deal at .90c ents a share.
You may recall that news is out that Hexo turned down a $3.00 per share offer from Tilray in November 2021
As well, the 'partnership' also came at a cost of $20 million annually for debt servicing, $18 million annually fro 'advisory fees', and Hexo agreeing to buy all product for any international sales they might get - from Tilray.
You seriously want to post articles about the Tilray 'partnership'?
quinlash - (5/20/2022 1:06:13 PM)
RE:All this talk about S&P
That article is from 2021 and it relates to HEXO Corp no longer being part of the medical index, nothing to do with it's standing on the TSX / NYSE nor NASDAQ. The stock should just be listed as a Cannabis Stock IMHO and not medical.
In 2022 HEXO Corp is now partnering with Tilray Brands, how about bringing up those articles ?